Plain-English translation of NCT04910269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial was testing whether a medication called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG) could help people with early COVID-19 avoid hospitalization. Half of the participants received this medication as a single infusion along with their regular COVID care, while the other half received a placebo infusion. Researchers were looking at whether this treatment could improve outcomes by day 7 and beyond.
When COVID-19 is caught early, doctors want to prevent it from becoming severe enough to require hospitalization. This trial was designed to see whether giving patients antibodies from recovered COVID patients could help their immune systems fight the virus more effectively.
If you enrolled, you would receive either the study medication or a placebo as a single infusion. The study team would then monitor you through day 28, checking on your symptoms and whether you needed to be hospitalized. You would not be allowed to receive other experimental COVID treatments during this time, but you could continue your regular care like over-the-counter medicines.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States